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Abstract
Introduction: Muscle symptoms in systemic sclerosis (SSc) may originate from altered skeletal muscle
microcirculation, which can be investigated by means of blood oxygenation level dependent (BOLD) magnetic
resonance imaging (MRI).
Methods: After ethics committee approval and written consent, 11 consecutive SSc patients (5 men, mean age
52.6 years, mean SSc disease duration 5.4 years) and 12 healthy volunteers (4 men, mean age 45.1 years) were
included. Subjects with peripheral arterial occlusive disease were excluded. BOLD MRI was performed on calf
muscles during cuff-induced ischemia and reactive hyperemia, using a 3-T whole-body scanner (Verio, Siemens,
Erlangen, Germany) and fat-suppressed single-short multi-echo echo planar imaging (EPI) with four different
effective echo times. Muscle BOLD signal time courses were obtained for gastrocnemius and soleus muscles:
minimal hemoglobin oxygen saturation (T2*min) and maximal T2* values (T2*max), time to T2* peak (TTP), and
slopes of oxygen normalization after T2* peaking.
Results: The vast majority of SSc patients lacked skeletal muscle atrophy, weakness or serum creatine kinase
elevation. Nevertheless, more intense oxygen desaturation during ischemia was observed in calf muscles of SSc
patients (mean T2*min -15.0%), compared with controls (-9.1%, P = 0.02). SSc patients also had impaired
oxygenation during hyperemia (median T2*max 9.2% vs. 20.1%, respectively, P = 0.007). The slope of muscle oxygen
normalization was significantly less steep and prolonged (TTP) in SSc patients (P<0.001 for both). Similar differences
were found at a separate analysis of gastrocnemius and soleus muscles, with most pronounced impairment in the
gastrocnemius.
Conclusions: BOLD MRI demonstrates a significant impairment of skeletal muscle microcirculation in SSc.
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Introduction
Systemic sclerosis (SSc) is a connective tissue disorder in
which vascular alterations and endothelial damage are
prominent and lead to progressive and widespread
microangiopathy with dysfunction of various organs
[1,2]. The impaired microcirculation may become clini-
cally apparent as Raynaud’s phenomenon, digital ulcers
(DU), pulmonary hypertension, or renal crisis [1,2].
About one third of SSc patients complain of muscle
weakness, 15% have objective muscle atrophy, and 10%
an elevated serum creatine kinase (CK) [3]. The exact
pathogenesis of the muscle involvement is unknown, but
muscle biopsies in SSc patients have demonstrated
increased fibrosis of the perimysium and epimysium
[4-6], intimal proliferation of the larger endomysial and
perimysial vessels, perivascular infiltrates or muscle
necrosis [4-8]. It is however unclear, if there is a func-
tional impairment of skeletal muscle microcirculation in
SSc patients.
Blood oxygenation level-dependent (BOLD) magnetic
resonance imaging (MRI) has been shown to be a valu-
able tool for the assessment of skeletal muscle microcir-
culation [9-11]. Derived from functional brain MRI
studies, this technique relies on the physiologic magnetic
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properties of hemoglobin and is therefore independent
from exogenous contrast agents [12]. Hemoglobin iron
changes its spin state from diamagnetic low-spin in the
oxygenated state to paramagnetic high-spin in the deoxy-
genated state [13]. This causes local magnetic field dis-
tortions in the surrounding tissue, which results in
dephasing of the proton signal, consecutively leading to a
signal decay with increasing intravascular deoxyhemoglo-
bin content [12]. Gradient echo (GE) MR sequences
emphasize this effect, leading to an increase of the appar-
ent transverse relaxation rate (1/T2*) and a decrease of
T2*[14]. Though being mainly determined by the oxygen
saturation in muscle microcirculation, BOLD signal also
depends on blood volume, hematocrit and inflow [10,15].
By provoking changes in the local muscle oxyhemoglobin
concentration via ischemia, reactive hyperemia, drugs or
muscle exercise, BOLD imaging can be used to assess
physiologic and pathologic alterations of micro- and
macrovascular pathologies [10,16-19].
These properties render muscle BOLD imaging a pro-
mising method for the assessment of the microangio-
pathic component in the muscular symptoms of SSc
patients. Despite a high prevalence of muscular com-
plaints and findings, a systematic evaluation of muscle
microperfusion has not yet been performed. The purpose
of this study was therefore to analyze the microcircula-
tion of two different calf muscle groups in SSc patients
using an ischemia/ reactive hyperemia paradigm, and to




The study protocol was approved by the institutional
review board and the local ethics committee. Consecutive
patients with SSc, as defined by the American College of
Rheumatology (ACR) [20] and healthy volunteers were
recruited at our institution. All subjects were required to
be older than 18 years of age, normotensive, to have a
normal peripheral pulse status and ankle-brachial indexes
(ABI) ≥ 0.9. Exclusion criteria were general contraindica-
tions to MRI such as cardiac pacemakers, ferromagnetic
implants, immobility, pregnancy and claustrophobia. All
subjects gave written informed consent according to the
declaration of Helsinki.
Muscle BOLD paradigm
Subjects were placed supine with feet first within the
magnet bore and had to rest at least 5 minutes before
starting the examination to minimize the degree of
venous filling of the calf (Figure 1). A conventional leg-
sphygmomanometer cuff was fixed at mid-thigh level.
Ischemia of the leg was achieved by fast manual inflation
of the cuff to an end occlusion pressure of 50 mmHg
above the individual brachial systolic blood pressure.
After 180 s of cuff compression, the cuff was released
quickly by opening the air valve. Muscle BOLD imaging
was performed during the first 60 s in the resting state
(baseline), the following 180 s of ischemia and during
reactive hyperemia until recovery for a further 400 s.
Overall, 320 consecutive scans were performed within a
total acquisition time of 640 s.
MRI technique
All muscle BOLD MRI measurements were performed on
a 3-T whole-body scanner (Verio, Siemens Medical Solu-
tions, Erlangen, Germany) [11]. A fat-suppressed, T2*-
weighted, single, short multi-echo echo planar imaging
(EPI) sequence was used. Four axial slices (slice thickness
5 mm, gap 5 mm) were positioned in the upper left calf at
maximum diameter. Imaging parameters were as described
previously [11]. EPI images were supplemented with anato-
mical reference images of the four corresponding slices
using a T1-weighted, spin-echo sequence (Figure 2).
T2* time courses were obtained from rectangular
regions-of-interest (ROIs) within the soleus and gastro-
cnemius muscle using BrainVoyager (Brain Innovation B.
V., Maastricht, Netherlands). The ROIs were chosen to
exclude pixels of large vessels. All T2* time-courses were
normalized with respect to baseline and averaged over
the four acquired slices in each subject. Five curve para-
meters for the mean T2* time course of every subject
Figure 1 Imaging setup of the ischemia/reactive hyperemia
paradigm conducted with a conventional leg
sphygmomanometer wrapped around the middle of the thigh
and flexible array coils. To prevent compression of the calf
muscles the lower leg is supported at knee and foot level.
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were determined (Figure 3): 1) T2*min: minimum T2*
value during ischemia relative to baseline; 2) T2*max:
hyperemia peak-value of T2* relative to baseline; 3) time
to T2* peak (TTP): time in seconds between cuff defla-
tion and T2*max; 4) declining slope (DS): T2* gradient
between T2*max and 60 s afterwards (DS60s) and between
T2*max and 120 s afterwards (DS120s); 5) T2* end-value
(EV): average T2* during the last 10 s of the 640 s mea-
surement, relative to baseline. T2*min is a BOLD para-
meters characteristic of the microcirculatory network
during ischemia, whereas T2*max , TTP, DS and EV are
key parameters of the hyperemia phase.
Statistical analysis
For each muscle, mean values of the curve parameters
were computed by averaging over all subjects belonging
to the same study group. In addition, mean time courses
of the two groups were calculated separately from indivi-
dual T2* time courses in the soleus and gastrocnemius
muscle. Statistical analysis of the curve parameters was
performed with the Sigma-Plot vs. 12.2 statistical package
(Systat Software Inc, San Jose, CA, USA). Curve para-
meters were compared between study groups by means
of two-sided, unpaired Student’s t-tests or Wilcoxon’s
rank sum tests after Kolmogorov-Smirnov testing for
normality. P-values lower than 0.05 were considered sta-
tistically significant. Relationships between clinical char-
acteristics and muscle BOLD parameters were computed
as Spearman’s rank-order or Pearson’s moment correla-
tion, as appropriate.
Results
Twelve healthy volunteers (four male) and eleven SSc
patients (five male) were recruited. The mean age of the
SSc patients was 52.6 years, (SD 10.0) and the mean age
of the volunteers was 45.1 years (SD 13.1). There was
no statistical age difference between the study groups.
None of the study participants had a known malignancy.
Figure 2 T1 images and T2* maps of the upper left calf region from a healthy volunteer and a patient with systemic sclerosis (SSc). T1
images are shown on the left and T2* maps on the right. (A) Healthy volunteer. (B) SSc patient. T1 images were correlated for anatomical
reference with the respective T2* maps.
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The average ankle brachial index was 1.1 (SD 0.08) in
the healthy volunteers and 1.16 (SD 0.08) in the SSc
patients (P= 0.15). The mean body mass index (BMI)
was 25.8 (SD 3.7) in the SSc patients and was similar to
that in the healthy controls (mean 23.6, SD 2.7, P =
0.13). None of the subjects had diabetes mellitus. Only
one of the subjects, a female SSc patient, had anemia
(hemoglobin concentration 118 g/L blood).
Most SSc patients lacked muscle symptoms (Table 1).
One male SSc patient however, had muscle atrophy with
symmetric proximal and distal muscle weakness; his
serum CK (normal value <190 U/L) was 1570 U/L. Gas-
trocnemius muscle biopsy in this patient revealed scat-
tered necrosis in the absence of inflammation or
centralized myonuclei. In a second male SSc patient, the
serum CK was slightly elevated (218 U/L). Five SSc
patients had a history DU; of these two had DU at the
time of imaging. None of the SSc patients had pulmon-
ary arterial hypertension, or a history of renal crisis. Five
patients were treated with prednisone at the time of
imaging, only one of these patients was treated with a
daily dose above 7.5 mg (15 mg). Seven patients received
a second immunosuppressive agent and no patient was
treated with iloprost or a phosphodiesterase-5 inhibitor;
one patient received bosentan.
Muscle BOLD MRI measurements were performed
successfully and were well-tolerated in all subjects. The
size of the ROIs in the soleus was 121 pixels (SD 36),
corresponding to a mean value of 4.8 cm2 (SD 1.4), and
in the gastrocnemius 152 pixels (SD 35), corresponding
to a mean value of 6.1 cm2 (SD 1.4). Figure 4 depicts
the mean T2* time courses of the soleus (Figure 4a) and
gastrocnemius muscles (Figure 4b) and the mean of
both muscles (Figure 4c) in SSc patients (red) and
healthy volunteers (blue). During ischemia, the T2*
value continuously decreased in both study groups.
However, in the patient group, the mean muscle BOLD
T2* value in both calf muscles dropped faster and to a
significantly lower value (T2*min -15.0%, SD 7.3), than in
the control group (-9.1%, SD 3.5, P = 0.021) (Table 2).
T2* quickly increased in both groups after cuff defla-
tion, resulting in a hyperemia peak that was significantly
reduced in SSc patients (median T2*max 9.2%, interquar-
tile range (IQR) 4.4, 17.5), compared to the control
group (20.1%, IQR 17.0, 29.6, P = 0.007). The median
TTP was 39.0 s (IQR 35.0, 56.0) in the patient group
and 33.5 s (IQR 29.5, 36.5) in the healthy volunteers (P
= 0.026). After T2* peaking, the muscle BOLD signal
decay was faster in the control group during the first 60
s than during the next 60 s in all muscles examined. In
both time periods, DS values were significantly shorter
in the healthy volunteers than in the SSc patients (Table
2). Finally, in both groups the T2* calf muscle time
course returned to approximately baseline values with a
EV mean value of -0.3, SD 2.7% in the SSc group and
-0.7, SD 4.2% in the control group (P= 0.77).
Within the SSc patient group, neither the severity of
skin involvement in terms of the modified Rodnan skin
score (mRSS), nor patient age, disease duration, or the
result of the six-minute walk test were correlated with any
BOLD parameter. There were also no significant differ-
ences in BOLD parameters with respect to limited and dif-
fuse cutaneous SSc subsets, or autoantibody subgroups.
When comparing T2* time courses between the soleus
and the gastrocnemius muscles in healthy volunteers,
the more oxidative soleus muscle had a slightly better
oxygenation during reactive hyperemia (T2*max), than
the more glycolytic gastrocnemius muscle (P = 0.016,
paired t-test), and a trend towards a faster return to
baseline in terms of DS values. When comparing the
muscle BOLD MRI curves of the soleus and gastrocne-
mius in the SSc population, the oxygenation of the gas-
trocnemius muscle during ischemia and reactive
hyperemia appeared to be more impaired than that of
the soleus muscle (Table 2, Figures 4a and 4b). Statisti-
cal significance was observed when T2*max values were
compared between soleus and gastrocnemius muscles in
SSc (P = 0.010, paired t-test).
Discussion
We investigated skeletal muscle microcirculation in SSc
patients using skeletal muscle BOLD MRI of the calf.
Muscle BOLD time courses revealed a pronounced
impairment of muscle microcirculation in SSc patients
compared to healthy volunteers. The overall characteris-
tics of the muscle T2* time course during ischemia and
reactive hyperemia in the group of healthy volunteers
were similar to those already published [10,11,15,17].
Figure 3 Key parameters of a typical blood oxygenation level-
dependent (BOLD) T2* signal time course in a healthy
volunteer. T2* is a magnetic resonance imaging signal.
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During the ischemia phase, T2* dropped to signifi-
cantly lower T2*min values in the SSc group compared
with the control group. This finding could be explained
by a reduced oxygen reservoir in the microcirculation
due to capillary loss or obliteration. After cuff deflation,
SSc patients showed a significant reduction of T2*max, a
marked prolongation of TTP, and decreased DS values
compared to healthy volunteers. These effects could also
be explained by a reduction of blood flow in the micro-
circulation due to precapillary occlusion or a reduction
of capillary density, that is, structural vasculopathy. A
reduced vasodilatation reserve or preponderance of
vasoconstrictor stimuli (that is, functional vasculopathy)
could also be responsible for the observed alterations.
Certainly, several of the listed phenomena could concur-
rently contribute to these findings. Irrespective of the
mechanisms, the observed changes in the curve charac-
teristics are most probably attributable to local altera-
tions of microcirculation, a known hallmark of SSc in
other organs [1,2].
Concerning intermuscular differences, BOLD signal
alterations between SSc patients and healthy volunteers
tended to be more pronounced in the gastrocnemius
muscle when compared with the soleus muscle. Soleus
muscle predominantly consists of slow twitch oxidative
muscle fibers, whereas the gastrocnemius muscle is
mostly composed of fast twitch glycolytic fibers [15].
The more pronounced impairment of the oxidative
soleus muscle in SSc than that of the more glycolytic
gastrocnemius muscle may be explained by differences
in the blood supply. The gastrocnemius is commonly
supplied by a single artery that divides into branches,
whereas at least five separate arteries successively enter
the soleus [21]. Therefore the blood supply to the soleus
may be more vulnerable to obliteration than that of the
gastrocnemius.
In several rheumatic disorders, a macrovascular invol-
vement has been postulated; however, the frequency of
atherosclerosis and its extent in SSc remain controver-
sial [22-24]. As we excluded subjects with pre-existing
peripheral artery occlusive disease (PAOD) from our
study, and the time courses of SSc patients differ sub-
stantially from those of patients with PAOD during
ischemia, our results primarily implicate small vessel
Table 1 Clinical characteristics of eleven patients with systemic sclerosis undergoing blood oxygenation level-
dependent MRI of the calf muscles
Characteristic Value
SSc disease characteristics
SSc duration by first non-Raynaud’s symptom, mean (years) 5.4, SD 5.0
SSc duration by onset of Raynaud’s phenomenon, mean (years) 6.8, SD 6.2
Diffuse cutaneous SSc, n 3
Limited cutaneous SSc, n 5
Other SSc, n 3
Modified Rodnan skin score, median 5, range 1-26
Antinuclear autoantibody positive, n 11
Anti-centromere autoantibodies positive, n 3
Anti-topoisomerase autoantibodies positive, n 5
PM-Scl autoantibodies positive, n 1
Erythrocyte sedimentation rate, mean (mm) 14, SD 12
Muscle parameters
Serum creatine kinase elevation, n 2
Muscle atrophy, n 1
Muscle weakness on manual muscle testing, n 1
Six-minute walk test distance, mean (meters) 449, SD 68
Cardiopulmonary function
Systolic blood pressure, mean (mmHg) 127, SD 17
Diastolic blood pressure, mean (mmHg) 78, SD 11
Systolic pulmonary arterial pressure by echocardiography, mean (mmHg) 23.7, SD 4.4
Forced vital capacity, mean % of normal 91.4, SD 18.6
Diffusing capacity of the lung for carbon monoxide, mean % of normal 73.1, SD 26.3
SSc therapy
Patients on prednisone, n 5
Patients on methotrexate, azathioprine, mycophenolate, or cyclophosphamide, n 7
SSc, systemic sclerosis; BOLD, blood oxygenation level-dependent; MRI, magnetic resonance imaging; n, number of patients.
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disease as the origin of the detected BOLD signal altera-
tions in skeletal muscle. A recent analysis of skeletal
muscle involvement in SSc patients via 99mTc sestamibi
scintigraphy similarly revealed significant impairment of
muscle perfusion compared with healthy volunteers [25].
Our study has several limitations. First, our study only
includes a relatively small and heterogeneous number of
patients and volunteers. However, even in this small col-
lection, highly significant BOLD key parameter altera-
tions could be demonstrated. Second, there were some
imbalances in age and BMI between the study groups.
Earlier studies demonstrated that BOLD time courses in
calf muscles are age- and BMI-dependent [11,17]. As
age and BMI differences were considerably larger in
these aforementioned studies (30 to 43 years), the effect
on our results is likely to be rather small. T2*min and
T2*max decrease in older persons, thus we might
underestimate the alterations in SSc in our study.
Although symptoms and findings indicative of muscular
involvement are frequent in SSc [3], the SSc-related myo-
pathy lacks a universally accepted gold standard for its
diagnosis and is heterogeneous. Muscle weakness in SSc
may also arise from extramuscular organ involvement
such as cardiac, cutaneous, or pulmonary complications,
or gastrointestinal malassimilation. Serum CK measure-
ments are not a sensitive diagnostic tool, because a sub-
stantial number of SSc patients with objective muscle
weakness or abnormal muscle histology have normal CK
Figure 4 Muscle blood oxygenation level-dependent (BOLD) time courses in patients with scleroderma and healthy controls. Time
courses for patients with scleroderma are shown in red and for healthy controls in blue in (A) the soleus and (B) the gastrocnemius muscle. (C)
Mean time courses over both muscle groups. T2* is a magnetic resonance imaging signal.
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levels [6,26]. Thus, BOLD MRI may become a valuable aid
in the differential diagnosis of muscle weakness, myalgia
and fatigue of SSc patients.
Most of the consecutive SSc patients included in this
study had a functional impairment of muscle microcir-
culation despite a relatively short SSc disease duration
and the absence of muscle symptoms and findings. This
suggests that skeletal muscle microangiopathy may be
an early and prevalent SSc characteristic, although only
a minority of patients with SSc-related myopathy has
biopsy-proven muscle microangiopathy [27]. Further
studies correlating muscle BOLD MRI findings with
clinical and histopathological data might be helpful in
discriminating the influence of different mechanisms on
the alternations in the T2* time courses in SSc patients
and disease subgroups. Future studies of BOLD MRI
may determine if the microcirculatory impairment is
reversible, or if it indicates irreversible muscle damage.
The cuff compression paradigm that is used allows the
examination of forearm, hand, calf, and foot muscles
and thus may be used for the determination of disease
state and progression. As Raynaud’s phenomenon typi-
cally appears on the digits and finger tip ulceration is a
common complication in SSc patients, it will be inter-
esting to investigate if BOLD MRI changes are more
pronounced in distal than proximal limb muscles and
whether they are reversible or preventable with thera-
peutic agents.
Conclusions
We provide the first in-vivo evidence for an impaired ske-
letal muscle microcirculation in SSc by performing skeletal
muscle BOLD MRI. Muscle BOLD MRI represents a sui-
table and non-invasive imaging method for SSc-associated
vasculopathy. Further studies are warranted to get addi-
tional insights into the mechanisms underlying muscle
BOLD signal alterations in patients with SSc. This method
provides a non-invasive diagnostic tool in the assessment
of muscle involvement in SSc, and perhaps also other
rheumatic conditions such as connective tissue diseases
and small vessel vasculitis.
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Table 2 Calf muscle blood oxygenation level-dependent
(BOLD) key parameters of all eleven patients with
systemic sclerosis (SSc) and twelve volunteers
Volunteers SSc patients P-value
T2*min (%)
Soleus, mean (SD) -10.3 (4.0) -13.4 (6.9) 0.20
Gastrocnemius, mean (SD) -8.0 (4.6) -18.0 (9.9) 0.005
Both, mean (SD) -9.1 (3.5) -15.0 (7.3) 0.021
T2*max (%)
Soleus, median (IQR) 26.4 (20.0, 30.6) 15.7 (6.5, 21.9) < 0.007
Gastrocnemius, median (IQR) 17.2 (9.4, 32.0) 4.3 (0.1, 6.4) 0.002
Both, median (IQR) 20.1 (17.0, 29.6) 9.2 (4.4, 17.5) 0.007
TTP (s)
Soleus, median (IQR) 32.0 (30.0, 35.5) 38.0 (34.0, 54.0) 0.037
Gastrocnemius, median (IQR) 34.0 (27.5, 37.3) 42.0 (38.0, 50.0) 0.002
Both, median (IQR) 33.5 (29.5, 36.5) 39.0 (35.0, 56.0) 0.026
DS60 s *10-4 (s
-1)
Soleus, mean (SD) -17.9 (4.9) -10.3 (5.7) 0.002
Gastrocnemius, mean (SD) -14.7 (6.1) -6.6 (7.0) < 0.001
Both, mean (SD) -16.5 (4.6) -7.3 (4.9) < 0.001
DS120 s *10-4 (s
-1)
Soleus, mean (SD) -14.8 (3.3) -6.2 (4.4) < 0.001
Gastrocnemius, mean (SD) -11.7 (5.6) -4.5 (4.9) 0.004
Both, mean (SD) -13.7 (4.1) -4.6 (3.6) <0.001
EV (%)
Soleus mean (SD) -0.3 (3.9) 1.0 (4.4) 0.45
Gastrocnemius, mean (SD) 0.8 ± 3.3 -0.3 (3.4) 0.41
Both, mean (SD) -0.7 (4.2) -0.3 (2.7) 0.77
Parameters were obtained for the soleus and gastrocnemius muscle. Normally
distributed parameters are provided as means with SD, non-normally
distributed parameters are provided as medians with interquartile ranges
(IQR). T2*min, ischemic minimum of T2*; T2*max, T2* peak value during reactive
hyperemia; TTP, time to peak; DS, declining slope after hyperemia peaking;
EV, T2* end value. T2*min, T2*max and EV were calculated relative to baseline.
DS60s and DS120s represent T2*declining slopes between T2*max and 60 s or
120 s afterwards.
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